Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2006

View Archived Issues

Reovirus may promote immune response to cancer

Studies detail intravenous safety and preclinical activity of lacosamide

Presentations outline agomelatine efficacy in treating depression

Phase II results with FTY-720 in multiple sclerosis encourage phase III program

Additional preclincal, clinical and pharmacokinetic data on denosumab presented

Seikagaku licenses inflammatory disease rights to CF-101 in Japan

Advaxis discusses phase II plans for Lovaxin C with FDA

Optimized IC-41 regimen studied in proof-of-concept trial for hepatitis C

UCB: pipeline overview

RotaTeq vaccine provided free in Nicaragua over three years

Pevion Biotech reports phase I testing of virosome-based breast cancer vaccine

ImmuFact IMP-321 studied in phase I disease-free melanoma trial

New retinoid RARgamma agonists claimed in recent Galderma patent

Pagoclone advances for stuttering, discontinued for premature ejaculation

Recent patents describe new agents for diabetes and related disorders

AT-9283 studied in phase I/II trial for hematological malignancies

Pharmacokinetics, efficacy and safety of sitagliptin in patients with type 2 diabetes

Novel compounds with potential in the treatment of metabolic disorders patented

Expanded access program opens for TMC-125

Orphan drug designation for atiprimod in carcinoid tumors

MKC-1 studied in hematological malignancies in new phase I trial

CytRx reports encouraging results from phase IIa ALS trial with arimoclomol

Remicade approved for chronic severe plaque psoriasis

Vectibix approved for metastatic colorectal cancer

Fampridine-SR meets all SPA efficacy criteria in MS walking study

New preclinical data on NXL-104, a novel beta-lactamase inhibitor

Essential oil component carvacrol may be useful in cancer and thromboembolic disorders

PBI-1308: new protein A mimetic against autoimmune diseases

Novel antioxidant compounds show benefit in a mouse model of amyotrophic lateral sclerosis

R&D highlights from the UBS Global Life Science Conference in New York: Astex Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...